01 · The Question
Should participants know what happens financially if the research injures them?
A consent form explains that a study procedure can cause injury but says nothing about what happens afterward. Will treatment be available? Who pays for it? Is compensation available? Whom should the participant contact?
These are not minor administrative details when meaningful injury is foreseeable. A participant deciding whether to accept research risk may reasonably want to know what support exists if that risk materializes.
In the United States, both HHS and FDA informed-consent requirements specifically address this issue for research involving more than minimal risk. The requirement is to explain whether compensation and medical treatment are available if injury occurs and, if so, what they consist of or where additional information can be obtained.
03 · What You Need to Know
Injury information is part of meaningful informed consent
U.S. HHS requirements specifically address research involving more than minimal risk
OHRP explains that the HHS informed-consent requirements include, for research involving more than minimal risk, an explanation of whether compensation is available and whether medical treatments are available if injury occurs. If they are available, participants should be told what they consist of or where further information can be obtained.
OHRP's consent guidance further states that these explanations should be consistent with sponsor and institutional policies. For research involving no more than minimal risk, the specific injury-compensation and medical-treatment explanation is not required under this provision and may sometimes be unnecessarily alarming when the risks do not involve physical injury.
This is a regulatory distinction, not a statement that participants in minimal-risk studies never deserve information about costs, support, or other consequences when such information is relevant. Other consent requirements, institutional policies, or study circumstances may still matter.
FDA-regulated clinical investigations contain a parallel requirement
FDA informed-consent regulations likewise require, for research involving more than minimal risk, an explanation of whether compensation and medical treatments are available if injury occurs and, if so, what they consist of or where further information may be obtained.
The similarity is important because researchers sometimes treat research-injury language as optional institutional boilerplate. In applicable regulated research, it is part of the information required for informed consent, not merely a courtesy paragraph.
Participants should also know whom to contact
HHS informed-consent requirements separately call for an explanation of whom to contact with questions about the research and participants' rights and whom to contact in the event of a research-related injury.
OHRP notes that research-related injury questions may sometimes appropriately be handled by an IRB, ombudsman, ethics committee, or another informed administrative body rather than solely by the investigator. The appropriate contact depends on the institution's arrangements.
A consent form should therefore give participants a usable pathway, not merely tell them that an institutional policy exists somewhere.
Medical treatment, payment for treatment, and compensation are different
A recurring source of confusion is the assumption that these terms mean the same thing.
Concept
Question it answers
Medical treatment
What care is available if injury occurs?
Payment of treatment costs
Who pays the bills for that care?
Compensation
Is financial compensation available for the injury or its consequences?
Insurance or indemnification
What financial mechanism or contractual arrangement may cover specified risks or liabilities?
Legal damages
What legal remedies may be available under applicable law?
A participant can therefore receive medical treatment without that treatment necessarily being free. A study can pay medical expenses without providing broader compensation. Compensation arrangements may exist without resolving every question of legal liability.
The consent process should describe the actual arrangement rather than collapsing these concepts into the reassuring but ambiguous sentence, “Treatment will be provided if you are injured.”
Do not promise free treatment unless free treatment is actually provided
Consent language should match sponsor and institutional arrangements. OHRP has provided examples showing that a consent form may, in some circumstances, state that an institution does not commit to free medical care or payment for unfavorable outcomes, provided the language does not improperly require participants to waive legal rights or release parties from negligence liability.
This can sound uncomfortable, but informed consent is not improved by making an arrangement appear more generous than it is. Participants need accurate information for decision-making.
Do not confuse disclosure with an entitlement to compensation
The regulatory requirement to explain whether compensation is available does not itself create a universal compensation scheme.
The answer may legitimately be that a particular form of compensation is available, that only specified treatment costs are covered, that ordinary billing arrangements apply, or that no financial compensation is offered under the study's arrangements. What matters for consent is that the explanation is accurate, understandable, and consistent with applicable requirements.
The broader question of who is responsible when research-related harm occurs therefore cannot be answered merely by reading the word “compensation” in a consent form.
Participants cannot simply be asked to waive legal rights
HHS regulations prohibit informed-consent language through which participants waive or appear to waive legal rights or release or appear to release the investigator, sponsor, institution, or their agents from liability for negligence. OHRP provides examples distinguishing permissible explanations of financial arrangements from prohibited exculpatory language.
Explaining an actual policy
May tell participants, when accurate, that an institution does not provide free treatment or that ordinary billing arrangements apply.
Waiving legal rights
May not require participants to give up claims or release investigators, sponsors, institutions, or their agents from negligence liability through prohibited exculpatory language.
The difference can be subtle enough that injury language should follow approved institutional and IRB or REC processes rather than being casually rewritten by individual investigators.
The information should be understandable, not merely technically present
Informed consent is a communication process rather than a signed-document exercise. OHRP describes it as involving disclosure of information needed for an informed decision, facilitation of understanding, and promotion of voluntariness.
Research-injury language should therefore answer the participant's practical questions. If I am injured, where do I go? Who do I contact? Is treatment available? Who may be billed? Is compensation available? Where can I obtain the authoritative details?
A paragraph written entirely in insurance and indemnification terminology may technically occupy the correct section while communicating very little.
New information may require the consent process to change
OHRP notes that the consent process and documentation should be revised when deficiencies are identified or when new information about reasonably foreseeable risks or potential benefits becomes available. Significant new information relevant to willingness to continue may also need to be communicated under applicable consent requirements.
If a previously unrecognized research-related injury occurs, the issue may therefore extend beyond compensating the affected participant. The study may need to reconsider what future participants are told about risk and what support arrangements are disclosed.
Do not wait until an injury occurs to determine what the consent language means
The research team should understand the injury provisions before enrolling participants. Investigators should know whom to contact, what can honestly be promised, what the sponsor covers, what the institution covers, and where participants should be directed for authoritative information.
This preparation matters when a participant becomes ill or injured during research . The immediate response is difficult enough without discovering at that moment that nobody on the study team understands the injury section of the consent form.
Watch Out
Never improvise an assurance such as “the study will pay for everything” after an injury unless that is actually established by the study's arrangements. A compassionate response can still be accurate: address immediate safety, explain the known process, and connect the participant with the person or office authorized to answer financial and compensation questions.
04 · A Practical Example
Two consent statements can sound similar but mean very different things
Hypothetical Example
A participant asks what happens if a study procedure causes an injury
A clinical study involves more than minimal risk. During consent, a prospective participant asks, “If this procedure injures me, will the study pay my hospital bill?”
Poor response
The researcher says, “Don't worry, you'll be taken care of,” even though the researcher does not know the sponsor or institution's financial arrangements.
Better response
The researcher explains the approved injury provisions accurately, distinguishes available medical treatment from who bears its cost, and identifies where the participant can obtain additional information.
Contact pathway
The participant is shown whom to contact if a research-related injury occurs and whom to contact for authoritative questions about the applicable arrangements.
Decision
The participant can incorporate that information into the decision about whether the study's risks are acceptable to them.
The purpose of the disclosure is not to reassure the participant at any cost. It is to make the consequences of accepting research risk sufficiently clear for an informed decision.
07 · A Quick Checklist
Before approving research-injury language for participants
Check that the consent materials:
Accurately state whether medical treatment is available if research-related injury occurs.
Distinguish availability of treatment from who will pay treatment costs when that distinction matters.
Accurately explain whether compensation is available under the study's actual arrangements.
Explain what available treatment or compensation consists of, or identify where participants can obtain authoritative additional information.
Provide a usable contact for research-related injury questions.
Match current sponsor, institutional, insurance, and other applicable arrangements.
Avoid implying free care, guaranteed payment, or compensation that has not actually been established.
Contain no prohibited language asking participants to waive legal rights or release research parties from negligence liability.
Use language understandable enough for participants to know what would practically happen if injury occurred.
11 · Cite this Guide
How to Cite This Guide
This guide is intended to be read, shared, and used in research, teaching, and academic work. If you draw on its ideas, explanations, or other content, please acknowledge the source by citing the guide. Doing so gives appropriate credit and helps your readers locate the original resource.
Recommended (Field Guide)
APA
MLA
Chicago
Copy Citation
